Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

A multi-society Delphi consensus statement on new fatty liver disease nomenclature

  • Mary E Rinella*
  • , Jeffrey V Lazarus
  • , Vlad Ratziu
  • , Sven M Francque
  • , Arun J Sanyal
  • , Fasiha Kanwal
  • , Diana Romero
  • , Manal F Abdelmalek
  • , Quentin M Anstee
  • , Juan Pablo Arab
  • , Marco Arrese
  • , Ramon Bataller
  • , Ulrich Beuers
  • , Jerome Boursier
  • , Elisabetta Bugianesi
  • , Christopher Byrne
  • , Graciela E Castro Narro
  • , Abhijit Chowdhury
  • , Helena Cortez-Pinto
  • , Donna Cryer
  • Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D Guy, Stephen A Harrison, Seung Up Kim, Bart Koot, Marko Korenjak, Kris Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R Morgan, Elisabeth Powell, Michael Roden, Manuel Romero-Gómez, Marcelo Silva, Shivaram Prasad Singh, Silvia C Sookoian, C Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N Newsome*, Luca Miele, NAFLD Nomenclature consensus group
*Autore corrispondente per questo lavoro
  • Sorbonne Université
  • Department of Veterans Affairs
  • Baylor College of Medicine
  • City University of New York
  • Western University
  • London Health Science Centre
  • Pontificia Universidad Católica de Chile
  • Hematology, Hospital Clínic
  • Academic Medical Center
  • Université d'Angers
  • University of Turin
  • University of Lisbon
  • University of Florida
  • Capital University - Egypt
  • Washington University St. Louis
  • Shanghai Jiao Tong University
  • Indiana University Bloomington
  • Yonsei University
  • Patients Association
  • Université Paris Cité
  • University of California at San Diego
  • PBC Foundation
  • Heinrich Heine University Düsseldorf
  • German Diabetes Center Düsseldorf
  • Deutsches Zentrum für Diabetesforschung
  • Hospital Universitario Virgen del Rocio
  • Universidad Austral
  • Newcastle University
  • National and Kapodistrian University of Athens
  • IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano
  • University of Milan
  • University of Cincinnati
  • Recep Tayyip Erdogan University
  • Barcelona Institute for Global Health

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

Unlabelled: The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. Methods: A modified Delphi process was led by three large pan-national liver associations. Consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. Results: A total of 236 panellists from 56 countries participated in four online surveys and two hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83% and 78%, respectively. 74% of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms 'non-alcoholic' and 'fatty' were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease (SLD) was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least one of five cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic SLD. A new category, outside pure MASLD, termed MetALD was selected to describe those with MASLD who consume greater amounts of alcohol per week (140 to 350 g/week and 210 to 420 g/week for females and males respectively). Conclusions: The new nomenclature and diagnostic criteria are widely supported, non-stigmatising and can improve awareness and patient identification.
Lingua originaleInglese
pagine (da-a)N/A-N/A
RivistaHepatology
VolumePublish Ahead of Print
Numero di pubblicazioneN/A
DOI
Stato di pubblicazionePubblicato - 2023

All Science Journal Classification (ASJC) codes

  • Epatologia

Keywords

  • N/A

Fingerprint

Entra nei temi di ricerca di 'A multi-society Delphi consensus statement on new fatty liver disease nomenclature'. Insieme formano una fingerprint unica.

Cita questo